Remegen Ltd. has synthesized antibody-drug conjugates consisting of anti-CDCP1 antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.
Glioblastoma (GBM) is the most common and highly aggressive primary brain tumor in adults. MicroRNAs (miRNAs) are pleiotropic post-transcriptional regulators of oncogenic pathways, and frequently lose their tumor-suppressive function in GBM. Researchers from the Istituto Italiano di Tecnologia previously identified a group of 11 pro-neurogenic miRNAs that supports adult neurogenesis by jointly regulating multiple targets in mouse neural stem cells. Writing in Molecular Therapy Nucleic Acids, they present a study where they examined the expression of these 11 miRNAs across glioma grades and GBM subtypes in patients.
Ottimo Pharma Ltd. has obtained IND clearance from the FDA and advanced OTP-01 (jankistomig), an anti-PD-1/VEGFR2 antibody, into phase I for solid tumors. The first patient has been dosed and the study is open at sites in the U.S. and Australia.
Arbele Pte Ltd.’s ARB-1002 has been awarded orphan drug designation by the FDA for the treatment of pancreatic cancer. ARB-1002 is an antibody-drug conjugate comprising an anti-CDH17 monoclonal antibody chemically linked to a potent cytotoxic agent.
Securing a second major partnership with Sanofi SA – this time worth a potential $2.56 billion – Earendil Labs will provide its AI-driven discovery platform to find new therapeutics for autoimmune and inflammatory diseases.
Scientists at Healzen Therapeutics Co. Ltd. and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has disclosed antibody-drug conjugates consisting of antibodies covalently linked to antitumor drugs through a linker reported to be useful for the treatment of cancer.
Crescent Biopharma Inc. has announced regulatory clearances of IND applications for CR-001 (SKB-118), a PD-1 x VEGF bispecific antibody, and CR-003 (SKB-105), an integrin β-6 (ITGB6)-targeted antibody drug-conjugate (ADC), both being developed for the treatment of advanced solid tumors.
Ernexa Therapeutics Inc. has successfully completed a pre-IND meeting with the FDA, setting a pathway toward submitting an IND and initiating a first-in-human trial for the treatment of ovarian cancer, expected in the second half of this year.
Ascentage Pharma Group International has obtained IND approval from the FDA for its BTK-targeted protein degrader APG-3288. A phase I study will be conducted in patients with relapsed or refractory B-cell malignancies.
RSS
